An experimental molecule that blocks an enzyme overactive in fat and aging muscle, helping cells retain fuel-and-repair compounds and burn fat. In obese mice it cut fat, improved blood sugar, and eased fatty liver; in old mice it aided muscle recovery. No human studies exist, and it is sold without quality control. (Full Review)
| Marker | Target | Why |
|---|---|---|
| Fasting glucose | 75–90 mg/dL | Tracks the glucose-control benefit |
| Fasting insulin | 2–5 µIU/mL | Detects insulin-sensitivity change |
| HbA1c | < 5.4% | Longer-term glucose average |
| ALT / AST | < 25 U/L (both) | Screens for the liver-fat benefit and liver stress/harm |
| Lipid panel | Triglycerides < 80 mg/dL; HDL > 50 mg/dL | Animal data show cholesterol and triglyceride reductions |
| Homocysteine | 5–7 µmol/L | Watches the methylation pathway the drug alters |
| hs-CRP | < 1.0 mg/L | General marker of systemic inflammation |
Cadence: Baseline before first dose; reassess at 8–12 weeks, then every 3–6 months if use continues